Kaitlyn Eddy
Principal Engineer, Delivery, Device, and Connected Solutions (DDCS) Eli Lilly
Kaitlyn Eddy is a Principal Engineer in Drug Delivery & Devices at Eli Lilly and Company. In this role, Kaitlyn supports preclinical studies evaluating central nervous system drug biodistribution, contributing engineering and neuroscience expertise to Lilly’s efforts to advance novel therapeutics to the brain and spinal cord. With 8 years at Lilly, Kaitlyn has supported a range of CNS delivery efforts for the team, working at the intersection of device design, pharmacology, and translational research to help characterize how therapies distribute within the CNS. Kaitlyn is particularly interested in novel routes of administration for CNS-targeted therapeutics, as well as emerging technologies to more precisely evaluate and predict drug biodistribution in the brain. Kaitlyn holds a Master’s degree in Biomedical Engineering, with a focus in Neuroengineering, from Johns Hopkins University.
Seminars
- A review of current methodologies used to measure drug biodistribution in the CNS, including terminal and non-terminal modalities
- Advantages/disadvantages of common modalities, including optical imaging, PET/CT, ELISA, and PCR
- Translation of methodologies across species/challenges in larger animal models, including differences in BBB permeability, CSF turnover and volume
